Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

RIBOFLAVIN deficiency in rheumatic Diseases: A call for clinical trials.

Rheumatology and immunology research·2026

Same author

Polyarteritis nodosa and antiphospholipid syndrome: a systematic review of a rare and challenging overlap between vasculitis and thrombotic vasculopathy.

Clinical rheumatology·2026

Same author

Intermittent hydrarthrosis (periodic synoviosis): A narrative review.

Autoimmunity reviews·2026

Same author

Antidotes in Homeopathy: Classical Doctrine, Clinical Relevance and Scientific Re-interpretation.

Homeopathy : the journal of the Faculty of Homeopathy·2026

Same author

Multiple Tophi and Tophus Aspirate in a Gouty Patient.

The Israel Medical Association journal : IMAJ·2026

Same author

Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis.

Rheumatology and therapy·2026

Search research articles

Related Experiment Video

Updated: May 26, 2026

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

Optic neuritis after infliximab therapy.

César Faillace, João Ricardo Maltez de Almeida, Jozélio Freire de Carvalho

Rheumatology International

|December 27, 2011

Summary

Anti-tumor necrosis factor (TNF) agents can cause demyelinating diseases like optic neuritis (ON). Withdrawal of TNF blockers and glucocorticoid treatment led to a good outcome in a rheumatoid arthritis patient experiencing ON.

Area of Science:

Neuroimmunology
Rheumatology
Ophthalmology

Background:

Tumor necrosis factor (TNF) inhibitors are used to treat autoimmune diseases.
Demyelinating diseases, including optic neuritis (ON), have been reported in patients using anti-TNF agents.
Twenty-two cases of TNF blocker-induced ON exist in the literature.

Observation:

A 53-year-old woman with refractory rheumatoid arthritis developed ON.
The patient experienced ON after her fourth dose of infliximab.
Symptoms of ON resolved favorably after discontinuing the anti-TNF agent and initiating glucocorticoid therapy.

Findings:

This case adds to the literature on TNF blocker-induced ON.
The review of previous cases provides further context for this adverse event.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: May 26, 2026

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

Published on: March 1, 2017

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Prompt withdrawal of the offending agent and appropriate treatment are crucial for managing ON.

Implications:

Clinicians should be aware of the potential for ON in patients treated with TNF inhibitors.
Early recognition and management of ON can lead to favorable outcomes.
Further research may elucidate the mechanisms underlying TNF inhibitor-associated demyelination.